ReViral Ltd.'s potential respiratory syncytial virus (RSV) infection therapy, RV521, has markedly reduced viral titers in a Phase IIa study, findings that move the small molecule further along the pipeline for investigational RSV products, a therapeutic area that has attracted the attention of big pharma, keen to develop new therapies for the significant unmet clinical need.
In healthy adults who developed RSV infections after intranasal administration of the virus, ReViral's investigational oral RSV fusion inhibitor, RV521, significantly reduced viral load, reduced total mucus weight and reduced clinical
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?